194 related articles for article (PubMed ID: 25930121)
1. Lactate dehydrogenase inhibitors sensitize lymphoma cells to cisplatin without enhancing the drug effects on immortalized normal lymphocytes.
Manerba M; Di Ianni L; Fiume L; Roberti M; Recanatini M; Di Stefano G
Eur J Pharm Sci; 2015 Jul; 74():95-102. PubMed ID: 25930121
[TBL] [Abstract][Full Text] [Related]
2. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.
Vettraino M; Manerba M; Govoni M; Di Stefano G
Anticancer Drugs; 2013 Sep; 24(8):862-70. PubMed ID: 23797802
[TBL] [Abstract][Full Text] [Related]
3. Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase.
Manerba M; Vettraino M; Fiume L; Di Stefano G; Sartini A; Giacomini E; Buonfiglio R; Roberti M; Recanatini M
ChemMedChem; 2012 Feb; 7(2):311-7. PubMed ID: 22052811
[TBL] [Abstract][Full Text] [Related]
4. Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways.
Farabegoli F; Vettraino M; Manerba M; Fiume L; Roberti M; Di Stefano G
Eur J Pharm Sci; 2012 Nov; 47(4):729-38. PubMed ID: 22954722
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells.
Han X; Sheng X; Jones HM; Jackson AL; Kilgore J; Stine JE; Schointuch MN; Zhou C; Bae-Jump VL
J Hematol Oncol; 2015 Jan; 8():2. PubMed ID: 25631326
[TBL] [Abstract][Full Text] [Related]
6. Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells.
Fiume L; Vettraino M; Carnicelli D; Arfilli V; Di Stefano G; Brigotti M
Biochem Biophys Res Commun; 2013 Jan; 430(2):466-9. PubMed ID: 23237800
[TBL] [Abstract][Full Text] [Related]
7. LDH inhibition impacts on heat shock response and induces senescence of hepatocellular carcinoma cells.
Manerba M; Di Ianni L; Govoni M; Roberti M; Recanatini M; Di Stefano G
Eur J Pharm Sci; 2017 Jul; 105():91-98. PubMed ID: 28501492
[TBL] [Abstract][Full Text] [Related]
8. Lactate dehydrogenase inhibitors can reverse inflammation induced changes in colon cancer cells.
Manerba M; Di Ianni L; Govoni M; Roberti M; Recanatini M; Di Stefano G
Eur J Pharm Sci; 2017 Jan; 96():37-44. PubMed ID: 27622920
[TBL] [Abstract][Full Text] [Related]
9. Lactate dehydrogenase inhibition affects homologous recombination repair independently of cell metabolic asset; implications for anticancer treatment.
Balboni A; Govoni M; Rossi V; Roberti M; Cavalli A; Di Stefano G; Manerba M
Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129760. PubMed ID: 33035602
[TBL] [Abstract][Full Text] [Related]
10. Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer.
Wangpaichitr M; Wu C; Li YY; Nguyen DJM; Kandemir H; Shah S; Chen S; Feun LG; Prince JS; Kuo MT; Savaraj N
Oncotarget; 2017 Jul; 8(30):49275-49292. PubMed ID: 28525376
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors.
Fiume L; Vettraino M; Manerba M; Di Stefano G
Pharmacol Res; 2011 Apr; 63(4):328-34. PubMed ID: 21168502
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Strategies Toward Lactate Dehydrogenase Within the Tumor Microenvironment of Pancreatic Cancer.
Moir JAG; Long A; Haugk B; French JJ; Charnley RM; Manas DM; Wedge SR; Mann J; Robinson SM; White SA
Pancreas; 2020; 49(10):1364-1371. PubMed ID: 33122526
[TBL] [Abstract][Full Text] [Related]
13. Impairment of aerobic glycolysis by inhibitors of lactic dehydrogenase hinders the growth of human hepatocellular carcinoma cell lines.
Fiume L; Manerba M; Vettraino M; Di Stefano G
Pharmacology; 2010; 86(3):157-62. PubMed ID: 20699632
[TBL] [Abstract][Full Text] [Related]
14. Lactate Dehydrogenase Inhibition: Biochemical Relevance and Therapeutical Potential.
Laganá G; Barreca D; Calderaro A; Bellocco E
Curr Med Chem; 2019; 26(18):3242-3252. PubMed ID: 28183261
[TBL] [Abstract][Full Text] [Related]
15. Pyruvate dehydrogenase complex and lactate dehydrogenase are targets for therapy of acute liver failure.
Ferriero R; Nusco E; De Cegli R; Carissimo A; Manco G; Brunetti-Pierri N
J Hepatol; 2018 Aug; 69(2):325-335. PubMed ID: 29580866
[TBL] [Abstract][Full Text] [Related]
16. Effects of the suppression of lactate dehydrogenase A on the growth and invasion of human gastric cancer cells.
Liu X; Yang Z; Chen Z; Chen R; Zhao D; Zhou Y; Qiao L
Oncol Rep; 2015 Jan; 33(1):157-62. PubMed ID: 25394466
[TBL] [Abstract][Full Text] [Related]
17. Lactate dehydrogenase inhibition: exploring possible applications beyond cancer treatment.
Di Stefano G; Manerba M; Di Ianni L; Fiume L
Future Med Chem; 2016 Apr; 8(6):713-25. PubMed ID: 27054686
[TBL] [Abstract][Full Text] [Related]
18. Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors.
Rupiani S; Buonfiglio R; Manerba M; Di Ianni L; Vettraino M; Giacomini E; Masetti M; Falchi F; Di Stefano G; Roberti M; Recanatini M
Eur J Med Chem; 2015 Aug; 101():63-70. PubMed ID: 26114812
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of lactate dehydrogenase activity as an approach to cancer therapy.
Fiume L; Manerba M; Vettraino M; Di Stefano G
Future Med Chem; 2014 Mar; 6(4):429-45. PubMed ID: 24635523
[TBL] [Abstract][Full Text] [Related]
20. Antitumor and chemosensitizing action of dichloroacetate implicates modulation of tumor microenvironment: a role of reorganized glucose metabolism, cell survival regulation and macrophage differentiation.
Kumar A; Kant S; Singh SM
Toxicol Appl Pharmacol; 2013 Nov; 273(1):196-208. PubMed ID: 24051182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
